Company news

Annexon, Inc. news in 2023

Annexon, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 26, 2023

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

December 19, 2023

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

December 19, 2023

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

December 19, 2023

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 21, 2023

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

November 12, 2023

Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

November 8, 2023

Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy

October 23, 2023

Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)

October 9, 2023

Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference

September 18, 2023

Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results

August 6, 2023

Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

July 29, 2023

Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

July 26, 2023

Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023

July 23, 2023

Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

May 23, 2023

Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress

May 7, 2023

Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

March 5, 2023

Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference

February 26, 2023

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

January 7, 2023

Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio

January 5, 2023

Decks in 2023